In a study published in Cell Stem Cell, scientists tested retinal pigment epithelial stem cells in a phase 1/2a clinical trial. The cells were obtained from adult postmortem eye tissue. These ...

The research team is now monitoring 12 more participants who received higher doses of 150,000 and 250,000 cells. If no safety ...

A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...

The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...

Coave Therapeutics has announced its lead gene therapy program, CoTx-101, for the treatment of retinal vascular diseases, ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...

On track to report topline 56-week data for LUGANO in mid-2026 with LUCIA data to closely follow – WATERTOWN, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a ...

Age-related macular degeneration (AMD) is one of the leading causes of vision loss among adults over 65. This condition ...

The gene therapy will utilize the firm's suprachoroidal vector coAAV-SCS, which it says will be an effective and less burdensome treatment alternative.